203 related articles for article (PubMed ID: 32735939)
1. Roflumilast: A potential drug for the treatment of cognitive impairment?
Sugin LJS; Murugesan A; Bindu M; Sunil KN
Neurosci Lett; 2020 Sep; 736():135281. PubMed ID: 32735939
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Jabaris SS; Sumathy H; Girish R; Narayanan S; Sugumar M; Saravana Babu C; Thanikachalam S; Thanikachalam M
Brain Res; 2015 Oct; 1622():279-91. PubMed ID: 26168894
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
4. Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
Hasan N; Zameer S; Najmi AK; Parvez S; Yar MS; Akhtar M
Pharmacol Rep; 2021 Oct; 73(5):1287-1302. PubMed ID: 33860460
[TBL] [Abstract][Full Text] [Related]
5. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
[TBL] [Abstract][Full Text] [Related]
6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
[TBL] [Abstract][Full Text] [Related]
8. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
9. A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.
Possemis N; Verhey F; Prickaerts J; Blokland A; Ramakers I
Trials; 2024 Mar; 25(1):162. PubMed ID: 38438923
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
11. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
13. The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Barreiro E; Puig-Vilanova E; Salazar-Degracia A; Pascual-Guardia S; Casadevall C; Gea J
J Appl Physiol (1985); 2018 Aug; 125(2):287-303. PubMed ID: 29648516
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
Field SK
Expert Opin Investig Drugs; 2008 May; 17(5):811-8. PubMed ID: 18447606
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast attenuates cognitive deficits in estrogen insufficient rats.
Goyal A; Garabadu D
Behav Pharmacol; 2020 Oct; 31(7):671-687. PubMed ID: 32516271
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
20. Severe multi-refractory Sneddon-Wilkinson disease, with fast response to oral roflumilast treatment.
Peñuelas Leal R; Grau Echevarría A; Labrandero Hoyos C; Blaya Imbernon D; Lorca Sprohnle J; Finello M; Mayo Martinez F; Zaragoza Ninet V
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e467-e469. PubMed ID: 38059421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
